Japanese Companies Are Gearing Up To Challenge U.S. Biotechnology Lead

WASHINGTON—A decade ago, the United States whetted the world’s appetite for biotechnology with a tempting platter of Western hors d’oeuvres including hybridoma technology, diagnostic tests, and a handful of new drugs. But aromas from biotech kitchens across the Pacific have some U.S. experts worned that the main course will be served with chopsticks, not forks. One telling sign of this is Rand SNell's business card. Apolitical scientist conducting a study for the U.S. Off

Written byElizabeth Pennisi
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WASHINGTON—A decade ago, the United States whetted the world’s appetite for biotechnology with a tempting platter of Western hors d’oeuvres including hybridoma technology, diagnostic tests, and a handful of new drugs. But aromas from biotech kitchens across the Pacific have some U.S. experts worned that the main course will be served with chopsticks, not forks.

One telling sign of this is Rand SNell's business card. Apolitical scientist conducting a study for the U.S. Office of Technology Assessment on biotechnology, Snell has his name and address printed in Japanese on the back side of his card. “I think the Japanese are very serious competitors,” he says. Noting that Japanese companies now dominate the consumer electronics industry, despite the fact that much of the core technology was developed in the U.S., Snell says, “The question is how to avoid repeating the historical mistakes that we made with electronics.

Fortunately for U.S. firms, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies